Saurabh Rajpal, MD
Adult Congenital Heart Disease · Columbus, OHNPI 1194956482
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $21,645 of the $31,529 with a category attached, or 68.7%. Actelion Pharmaceuticals US, Inc. accounts for 90.1% of it on its own, with 9 other manufacturers making up the rest. 2025 is the largest year on record at $23,097, more than ten times the $21 reported in 2021.
Across 60 payments — averaging $525.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$28K
- Medtronic$3K
- Zimmer Biomet$150
- Abbott$101
- Merck$98
- Novo Nordisk$74
- plus $114 from 4 others
Across 12 payments — averaging $3799.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$46K
What the payments were for
- Consulting fees$4,36014%
- Speaking & faculty fees$21,64569%
- Travel & lodging$3,55511%
- Food & beverage$1,9486%
- Education$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 27 | $28,392 |
| Medtronic | 19 | $2,599 |
| Zimmer Biomet | 1 | $150 |
| Abbott | 1 | $101 |
| Merck | 1 | $98 |
| Novo Nordisk | 3 | $74 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $40 |
| Pfizer | 2 | $39 |
| United Therapeutics Corporation | 1 | $21 |
| Lilly USA, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPSUMIT$27,766
- UPTRAVI$22,596
- HARMONY$1,971
- mymobility Platform$150
- AMPLATZER AMULET$101
How this compares
Too few adult congenital heart disease providers in Ohioto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tyvaso DpiTreprostinil | 88 | $2,077,191 |
| OpsumitMacitentan | 141 | $1,755,028 |
| UptraviSelexipag | 50 | $1,233,929 |
| Ambrisentan | 21 | $102,934 |
| Tadalafil | 122 | $68,439 |
| FarxigaDapagliflozin Propanediol | 12 | $14,334 |
| Sildenafil Citrate | 28 | $5,709 |
| EliquisApixaban | 14 | $5,371 |
| Metoprolol Succinate | 23 | $282 |
| Klor-Con M20Potassium Chloride | 11 | $252 |
| Furosemide | 16 | $88 |
| Losartan Potassium | 12 | $87 |
| Spironolactone | 13 | $47 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $28,392 | $2,988,957191 claims |
| PfizerEliquis | $39 | $5,37114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few adult congenital heart disease providers in Ohioon file to place this against a meaningful peer group, so we don't.
Other adult congenital heart disease in Columbus
- Curtis DanielsColumbus$20K
- Elisa BradleyColumbus$0
- May MahColumbus$0
- William KayFairfield$4K
- Alexander OpotowskyCincinnati$3K
- Clayton SmithCincinnati$832
- Hassan AlmeneisiCincinnati$534
- Margaret FuchsCleveland$370
- Isla McClellandDublin$328
- Nicole BrownCincinnati$104
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.